WALTHAM, Mass., July 23, 2015 /PRNewswire/ -- Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, announced today the election of Geoffrey S. Ginsburg, M.D., Ph.D. to the Company's Board of Directors, effective immediately. Dr. Ginsburg is a founding director of the Center for Applied Genomics & Precision Medicine and also a professor of Medicine, Pathology and Biomedical Engineering, both at Duke University.
"We are thrilled that Geoff Ginsburg has joined the Alere Board of Directors," said Gregg J. Powers, Chairman of the Board of Alere. "With work spanning oncology, infectious disease, cardiovascular disease and metabolic disorders and research addressing the challenges of translating genomic information into medicine and integrating precision medicine into health, Geoff brings to our Board a wealth of expertise in applied science and experience in genomics, molecular diagnostics and personalized medicine. We look forward to his contributions in guiding the future direction of Alere."
"I am delighted to join the Alere Board of Directors and to help the Company fulfill its vision of bringing high-performance, rapid diagnostics to the point of care globally," said Geoffrey S. Ginsburg, Professor of Medicine, Pathology and Biomedical Engineering at Duke University. "I congratulate the Company on its recent progress and business transformation."
In addition to his current positions at Duke University, Dr. Ginsburg also serves as an expert panel member for Genome Canada, as a member of the Board of External Experts for the National Heart, Lung and Blood Institute, as Co-Chair of the Institute of Medicine's Roundtable on Genome-Based Research to Human Health, as a member of the advisory council for the National Center for Accelerating Translational Science, as co-Chair of the Cures Acceleration Network, co-chair of the Global Genomic Medicine Collaborative, and as a member of the World Economics Forum's Global Agenda Council on the Future of the Health Sector. Dr. Ginsburg worked at Millennium Pharmaceuticals, Inc. from 1997 to 2004, serving as senior program director for cardiovascular diseases and later as Vice President of Molecular and Personalized Medicine, where he was responsible for developing pharmacogenomics and biomarker strategies for therapeutics.
About Alere Alere believes that when diagnosing and monitoring health conditions, Knowing now matters™. Alere delivers on this vision by delivering reliable and actionable information through rapid diagnostic tests, enhancing clinical and economic health outcomes globally. Headquartered in Waltham, Mass., Alere focuses on rapid diagnostics for infectious disease, cardiometabolic disease and toxicology. For more information on Alere, please visit www.alere.com.
SOURCE Alere Inc.